Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial
By Kashish Tandon
Sept 12 (Reuters) -F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for infections caused by drug resistant "superbugs" or microbes.
The funding also includes investment from Novo Holdings that holds a controlling stake in Novo Nordisk NOVOb.CO. The latest round would help the UK-based company complete a global late-stage study of its lead drug, olorofim.
The drug is being developed to treat invasive fungal infections including aspergillosis - a rare infection that is resistant to antifungal medication.
The U.S. Food and Drug Administration rejected the drug last year, citing the need for more data after a mid-stage trial.
The ongoing late-stage study for the drug could help get approval in Europe and Asia too, F2G CFO Ralf Schmid said.
Schmid said olorofim could be launched in the United States "as early as 2026," and its peak sales could cross $1 billion.
The pipeline for new antibiotics and antifungal drugs has suffered several setbacks over the years amid a wave of bankruptcies among smaller biotech firms as they struggled with anemic investments.
In 2020, 20 large drugmakers founded the AMR Action Fund to boost the pipeline of antifungal and antibiotic drugs, with a target of enabling as much as four novel antibiotics to hit the market by 2030.
AMR Action Fund led the latest funding round for F2G, with other investors including ICG Life Sciences and Advent Life Sciences.
AMR Action Fund CEO Henry Skinner said the drug had a new mechanism, which is critically important for anti-infective treatments as microbes develop resistance to older drugs.
Olorofim could also target "a lot of fungus that are emerging as a much greater problem with global warming and climate change," said Skinner.
Reporting by Kashish Tandon in Bengaluru; Editing by Shinjini Ganguli
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
